For a third season, COVID-19 cases are rising ahead of the holidays, this time with a more recent variant driving infections.
Cases of JN. 1 infections rose from just more than 8% at the end of November to double digits by Dec. 9, according to CDC data.
International health experts say the sudden jump isn’t cause for concern—yet.
Here’s what you need to know:
What is JN.1?
The JN.1 variant is closely related to another omicron subvariant named BA.2.86, according to the CDC.
Health officials started tracking BA.2.86 in August but noticed some cases had a single change to the spike protein, the part of a virus that penetrates host cells to cause infection, according to the CDC.
JN.1 was first detected as its own variant in the United States in September, the CDC reported, and has since been identified in 11 countries.
The variant made up just 0.1% of cases at the end of October, according to CDC data, but that number has now increased exponentially.
“The continued growth of JN.1 suggests that it is either more transmissible or better at evading our immune systems,” the CDC said at the beginning of December.
This means the change to the spike protein may make it easier for the virus to get into cells than previous variants or make it harder for human immune systems to identify the virus as COVID-19.
International health experts also noted the trend, with JN.1 officially classified as its own variant by the World Health Organization on Dec. 19.
“Based on the available evidence, the additional global public health risk posed by JN.1 is currently evaluated as low,” the WHO said in a post on X, formerly known as Twitter. “Despite this, with the onset of winter in the Northern Hemisphere, JN.1 could increase the burden of respiratory infections in many countries.”
Does the updated COVID booster protect against JN.1?
The CDC says the JN.1 variant is closely related enough to previous variants that the updated COVID-19 booster shot will provide protection.
“The spike protein—called a ‘spike’ because it looks like tiny spikes on the virus’ surface—plays a crucial role in helping the virus infect people. Because of this, the spike protein is also the part of the virus that vaccines target, meaning vaccines should work against JN.1 and BA.2.86 similarly,” the CDC said.
The agency continued by saying it expects “treatments and testing to remain effective” against JN.1, in line with previous variants.
The most recent COVID-19 booster was approved by the Food and Drug Administration and then recommended by the CDC in September, but a large number of Americans have opted out of the shot.
Do I need the new COVID booster?
The vaccine is recommended for everyone over the age of six months, regardless of previous vaccine status, the CDC says.
Despite this, fewer and fewer Americans are adding the shot to their regular seasonal vaccines, like the flu shot.
By the middle of November, only 36 million adults and 3.5 million children had received the latest shot, equivalent to about 14% of the American public, ABC News reported.
That’s compared to the nearly 70% of Americans who completed the primary series of COVID-19 vaccines, McClatchy News reported.
Cases of JN.1 have seen some of the highest increases in Midwestern states, CDC data shows, correlating with a pocket of the U.S. that has been particularly hesitant to get the new shot.
Ahead of the holidays, the CDC reiterated the vaccine, masking and keeping your distance when you might be sick are still the most effective ways to prevent a COVID-19 infection and prevent its spread.
The agency said this also extends to other respiratory illnesses making the rounds this season.
“Many viruses spread more during the holiday season, so it is important to get all recommended vaccines, including flu, COVID-19 and RSV, as soon as possible,” the CDC said. “This will give you the best protection against these respiratory diseases, including while traveling and gathering with family and friends. These vaccines will also make your illness less severe if you do get sick.”
News
FDA Clears First-of-Its-Kind Nonmedication Treatment for PTSD
The FDA has cleared a system that uses brain activity data to personalize magnetic stimulation for PTSD, adding a new nonmedication treatment option. Every day in the United States, approximately 17.5 veterans die by suicide, [...]
FDA approves breakthrough drug to treat advanced pancreatic cancer
The Food and Drug Administration (FDA) approved on Wednesday a drug that could extend the survival of those with metastatic pancreatic cancer. The drug, called daraxonrasib, will be sold under the brand name Rasonque [...]
AI Decodes a Hidden DNA Signal Linked to Disease-Causing Mutations
Machine learning identifies the likely “initiator” and enables new predictions about DNA mutations that can cause disease. Every human cell depends on tens of thousands of genes being switched on at the right time [...]
Pope Leo Urges Global Response to Congo’s Deadliest Ebola Outbreak
Pope Leo called for international action to address the Ebola outbreak in the Democratic Republic of Congo. The epidemic has claimed over 2,500 lives and is the nation's largest recorded outbreak. The Pope emphasized [...]
Is there a summer COVID-19 surge this year? Yep, it’s ramping up again
Hantavirus. Ebola. West Nile. Measles. And, of course, cyclospora — that stomach parasite making people miserable across the country. Americans have plenty to worry about this summer. But remember COVID-19? It may not be [...]
Natural Compound in Broccoli Could Help Treat a Rare, Incurable Neurological Disease
Swinburne researchers have discovered how broccoli could help treat an extremely rare and incurable disease that affects only about 200 Australians. A naturally occurring compound in broccoli is being investigated as a possible treatment [...]
Antibody recycling, FcRn and the next generation of biologics
FcRn plays a central role in regulating the half-life of IgG antibodies and albumin, making it a critical target in both antibody engineering and autoimmune disease therapy. This article explores the biology of FcRn, [...]
Ebola kills 2,300 in three months with no vaccine available for Congo’s deadliest ever outbreak
It’s Congo’s 17th outbreak, with a toll that has eclipsed that of the country’s 2018-2020 outbreak when 2,299 deaths out of 3,481 cases were recorded. The latest data shows 101 new cases and 33 [...]
Beyond an Agency: How AI, Creativity and Commercialization Are Converging Into a New Growth Model
At a moment when AI is forcing a fundamental rethink of how work gets done, the life sciences industry is grappling with a deeper question: what role should human creativity play in an increasingly [...]
New $60 Blood Test Detects Lung Cancer Without Costly DNA Sequencing
A simple blood test that detects chemical changes in DNA identified more than 90% of stage 2-4 lung cancers in an early study, without relying on costly DNA sequencing. Researchers at Tel Aviv University and collaborating [...]
Reducing drug development failures with human-relevant models and AI
Professor Joseph C. Wu of Stanford University explains how stem cells, human-relevant models and AI are helping researchers predict which drug candidates are most likely to succeed before clinical trials. Researchers now have access [...]
Half of vaccines are binned – ‘fridge-free’ versions could change that
Vaccines that do not need to be kept cool in a fridge have been successfully trialed in patients for the first time, say UK scientists. Currently, most vaccines need to be refrigerated or frozen [...]
Mushroom Mystery: The Fungus That Makes People See Tiny Humans
A mushroom sold in markets and served in restaurants in Southwest China has an unusual warning attached to it: cook it thoroughly, or you may start seeing tiny people. For decades, people have reported [...]
Artificial intelligence used to design brand new viruses
Artificial Intelligence has been used to design brand new viruses that are fully functional and can replicate in the laboratory, say US researchers. It is the first time whole genomes have been successfully designed [...]
Molecular Manufacturing: The Future of Nanomedicine – New book from NanoappsMedical Inc.
This book explores the revolutionary potential of atomically precise manufacturing technologies to transform global healthcare, as well as practically every other sector across society. This forward-thinking volume examines how envisaged Factory@Home systems might enable the cost-effective [...]
Moderna kicks off Phase I Ebola trial as Africa readies itself for research
If the Phase I trial is successful, Moderna plans to quickly initiate Phase II and Phase III trials of its Ebola vaccine. Moderna has initiated a Phase I trial of its mRNA Ebola vaccine [...]
